Vitro S.A.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vitro S.A. - overview
Established
1989
Location
Sevilla, -, Spain
Primary Industry
Healthcare IT
About
Vitro S. A. , based in Spain, specializes in biomedical research, focusing on innovative diagnostic solutions for oncology and infectious diseases, enhancing healthcare through advanced technology and rigorous quality control. Founded in 1989, Vitro S.
A. operates from Sevilla, Spain, focusing on developing diagnostic tools. The company has made strategic adjustments to enhance its offerings and remains under the leadership of CEO Javier Fernández. It has completed 2 deals, with the most recent in March 2022, when GED Capital shifted its investment to the GED Strategic Partnerships I fund, alongside other partners.
Vitro Master Diagnóstica specializes in the research, development, manufacturing, and commercialization of comprehensive diagnostic solutions primarily in oncology and infectious diseases. Their products include high-quality reagents, advanced instrumentation, and innovative software designed for histopathology and molecular diagnostics, aimed at supporting healthcare professionals in accurate disease diagnosis while optimizing laboratory resources. Vitro serves a diverse clientele, including hospitals, diagnostic laboratories, and research institutions across Spain, Portugal, and Turkey, with a commitment to continuous innovation through R&D investments. For the fiscal year 2023, Vitro S.
A. reported a revenue of USD 30. 55 mn and an EBITDA of USD 3. 28 mn, reflecting its operational efficiency within the healthcare sector.
In its pursuit of growth, Vitro S. A. plans to enhance its research and development efforts, focusing on launching new in vitro diagnostics platforms. The recent funding round in March 2022 will support new acquisitions and bolster R&D capabilities.
Vitro is also targeting expansion into new markets, including the United States and other international regions, to broaden its reach and impact in the healthcare industry.
Current Investors
Buenavista Equity Partners, Argentum, Headway Capital Partners
Primary Industry
Healthcare IT
Sub Industries
Healthcare IT
Website
www.vitro.bio
Verticals
Wearables & Quantified Self
Company Stage
Mature
Total Amount Raised
Subscriber access only
Vitro S.A. - timeline of key events
Vitro S.A. - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 13,598,096.5 | 14,394,541.6 | 14,519,082.8 | 15,691,076.1 | 17,852,532.9 | 33,309,300.2 | 37,639,604.9 | - | - | - |
| % Revenue Growth (YoY) | - | 5.9% | 0.9% | 8.1% | 13.8% | 86.6% | 13.0% | - | - | - |
| EBITDA (USD) | 1,411,891.9 | 1,297,284.8 | 1,623,421.1 | 2,733,391.8 | 2,904,720 | 13,121,895.7 | 8,331,002.9 | - | - | - |
| Operating Income (USD) | 530,503 | 444,481.3 | 403,004.5 | 578,776 | 671,126.2 | 10,354,872.5 | 4,924,901.9 | - | - | - |
| Operating Margin | 3.9% | 3.1% | 2.8% | 3.7% | 3.8% | 31.1% | 13.1% | - | - | - |
| % EBITDA Margin | 10.4% | 9.0% | 11.2% | 17.4% | 16.3% | 39.4% | 22.1% | - | - | - |
| NET Income (USD) | 521,558.8 | 499,637 | 1,312,560.8 | 4,375,188.4 | 761,085 | 7,961,723.5 | 3,569,420.7 | - | - | - |
| % Net Margin | 3.8% | 3.5% | 9.0% | 27.9% | 4.3% | 23.9% | 9.5% | - | - | - |
Vitro S.A. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary Buyout | Completed | Vitro S.A. | - | ||||||||
| Trade Sale | Completed | Cytognos, S.L | - | ||||||||
| Buyout | Completed | Vitro S.A. | - |
Displaying 1 - 3 of 3
Vitro S.A. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.